Cochrane continues to see strong activity, with solid sales growth helping maintain balanced market conditions.
Key Market Stats (February 2026)
Sales: 91 (+21.3% Y/Y)
New Listings: 154
Sales-to-New-Listings Ratio: 59%
Inventory: 284 (+44.9% Y/Y)
Months of Supply: 3.12
Benchmark Price: $553,500 (-3% Y/Y)
Average Price: $553,500 (benchmark context)
Detached benchmark price: $636,800 (+5.3% Y/Y).
What This Means
The rise in new listings has been largely offset by strong sales activity. With about three months of supply, Cochrane is shifting toward more balanced conditions.
Although benchmark pricing is slightly below last February due to prior quarterly pullbacks, prices edged up month-over-month in February.
Bottom Line: Cochrane remains competitive but balanced, with solid buyer activity and stable pricing trends.